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Abstract
Background: Translational medicine requires the integration of knowledge using
heterogeneous data from health care to the life sciences. Here, we describe a
collaborative effort to produce a prototype Translational Medicine Knowledge Base
(TMKB) capable of answering questions relating to clinical practice and
pharmaceutical drug discovery.
Results: We developed the Translational Medicine Ontology (TMO) as a unifying
ontology to integrate chemical, genomic and proteomic data with disease,
treatment, and electronic health records. We demonstrate the use of Semantic Web
technologies in the integration of patient and biomedical data, and reveal how such
a knowledge base can aid physicians in providing tailored patient care and facilitate
the recruitment of patients into active clinical trials. Thus, patients, physicians and
researchers may explore the knowledge base to better understand therapeutic
options, efficacy, and mechanisms of action.
Conclusions: This work takes an important step in using Semantic Web technologies
to facilitate integration of relevant, distributed, external sources and progress towards
a computational platform to support personalized medicine.
Availability: TMO can be downloaded from http://code.google.com/p/
translationalmedicineontology and TMKB can be accessed at http://tm.
semanticscience.org/sparql.
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A major element of personalized medicine involves the identification of therapeutic
regimes that are safe and effective for specific patients. This contrasts the “one-size-
fits-all” well-known concept of “blockbuster” drugs, which are considered safe and
effective for the entire population. The concept of targeted patient groups falls in-
between these two extremes with the identification of therapeutic regimes targeted to
be safe and effective for specific patient groups with similar characteristics [1]. A num-
ber of factors have contributed to a decline in the emphasis of blockbuster therapeutics
and a corresponding rise in the quest for tailored therapeutics or personalized medi-
cine. Essential to the realization of personalized medicine is the development of infor-
mation systems capable of providing accurate and timely information about potentially
complex relationships between individual patients, drugs, and tailored therapeutic
options. The demands of personalized medicine include integrating knowledge across
data repositories that have been developed for divergent uses, and do not normally
adhere to a unified schema. This paper demonstrates the integration of such knowl-
edge across multiple heterogeneous datasets. We show the formation of queries that
span these datasets, connecting the information required to support the goal of perso-
nalized medicine from both the research and the clinical perspectives.
Integration of the patient electronic health record (EHR) with publicly accessible
information creates new opportunities and challenges for clinical research and patient
care. For example, one challenge is that the complexity of the information provided to
the clinician must not impair the clinician’s ability to accurately and rapidly prescribe
drugs that are safe and effective for a specific patient, and covered by the patient’s
insurance provider. An example opportunity is that EHRs enable the identification of
adverse events and outbreak awareness and provide a rich set of longitudinal data,
from which researchers and clinicians can study disease, co-morbidity and treatment
outcome. Moreover, the increased desire to rapidly translate drug and gene-based drug
therapy to clinical practice depends on the comprehensive integration of the entire
breadth of patient data to facilitate and evaluate drug development [2]. Thus, EHR
integration could create the ideal conditions under which new or up-to-date evidence-
based guidelines for disease diagnosis and treatment can emerge. Although supplying
patient data to the scientific community presents both technical and social challenges
[3], a comprehensive system that maintains individual privacy but provides a platform
for the analysis of the full extent of patient data is vital for personalized treatment and
objective prediction of drug response [4]. The impetus to collect and disseminate rele-
vant patient-specific data for use by clinicians, researchers, and drug developers has
never been stronger. Simultaneously the impetus to provide patient-specific data to
patients in a manner that is accurate, timely, and understandable, has also never been
stronger.
This motivation takes specific form in the US where health care providers who want
stimulus-funded reimbursement from recent electronic health funding, to implement
or expand the use of electronic medical records (EMRs) in care practices, must achieve
“meaningful use.” An EMR is an electronic record of health-related information on an
individual that is created, gathered, managed, and consulted by licensed clinicians and
staff from a single organization who are involved in the individual’s health and care.
An electronic health record (EHR) is an aggregate electronic record of health-related
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than one health care organization and is managed and consulted by licensed clinicians
and staff involved in the individual’s health and care. By these definitions, an EHR is
an EMR with interoperability (i.e. integration to other providers’ systems). Achieving
meaningful use requires both using certified EHR technology and achieving documen-
ted objectives that improve the quality, safety, and efficiency of care while simulta-
neously reducing disparities, engaging patients and families in their care, promoting
public and population health, improving care coordination, and promoting the privacy
and security of EHRs (CMS 2010) [5]. A “certified” EHR must meet a collection of reg-
ulations and technical requirements to perform the required meaningful use functions
(ONCHIT 2010) [6]. Minimum meaningful use requirements include fourteen core
objectives, five out of ten specific objectives, and fifteen clinical quality measures (CMS
2010). These criteria, conditions, and metric achievements are all delayed and compli-
cated by the typical data fragmentation that occurs between the research and health
care settings and will continue until a “translational” ontology is available to bridge
activities, transferring data and entities between research and medical systems.
Translational medicine refers to the process by which the results of research done in
the laboratory are directly used to develop new ways to treat patients. It depends on
the comprehensive integration of the entire breadth of patient data with basic life
s c i e n c ed a t at of a c i l i t a t ea n de v a l u a t ed r u gd e v e l o p m e n t[ 2 ] .I nt h e1 9 9 0 s ,s e v e r a l
efforts related to data integration emerged, including the Archimedes Project and the
use of heterogeneous data integration, mathematical and computational modeling, and
simulation to expose the underlying dynamics and different individual treatment
response patterns clinicians observed in patients diagnosed with Major Depressive Dis-
order [7][8]. When information regarding the patient experience (symptoms, pharma-
cokinetics/pharmacodynamics, outcomes, side effects) can be directly linked to
biomedical knowledge (genetics, pathways, enzymes, chemicals, brain region activity),
clinical research can gain new insights in causality and potential treatments. Detailed
recordings of clinical encounters are a crucial component of this approach [9][10] and
devices such as personal electronic diaries aid both patient and clinician in capturing
accurate patient data of these accounts.
Electronic Medical Records now act as main repositories for patient data. As we con-
tinue to explore the intricate relationship between phenotype and genotype, these
records become a vital source for monitoring patients’ progression of disease. The pre-
sence of a given variation, as it relates to the appearance or absence of disease over
time, can be mapped as encounters are recorded by clinicians. Every result, encounter,
event, or diagnosis is recorded as a data item and includes a date. This rich longitudi-
nal data provide trends that show improvement or decline in state and occurrence or
absence of diagnostic criteria and can be used to guide treatment, provide prognosis,
or identify patients who are likely to respond to a potential treatment. The following
example illustrates the kinds of data we seek to integrate and analyze for clinical
research purposes. Carvedilol is prescribed to a given patient, while a number of blood
pressures and heart rate recordings are taken sequentially over time. If this patient
takes the medication as prescribed, we can easily observe trends and establish alerts to
adjust the medication, if necessary. Alternatively, the simultaneous occurrence of any
recorded side effects can be correlated more easily with potential causative agents.
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played for easy review by clinicians. Rich longitudinal data can also provide the oppor-
tunity to validate diagnostic procedures and otherwise catch discrepancies between
corresponding clinical reports. This application of longitudinal data is being investi-
gated in the World Wide Web Consortium (W3C) Health Care and Life Science Inter-
est Group (HCLSIG) within the context of breast cancer, where a radiology report is
followed by a biopsy and a pathology report. There should be a set of corresponding
observations within the two reports, with the pathology report corroborating the find-
ings of the radiology report [11].
Semantic Web technologies enable the integration of heterogeneous data using expli-
cit semantics, the expression of rich and well-defined models for data aggregation, and
the application of logic to gain new knowledge from the raw data [12]. Semantic tech-
nologies can be used to encode metadata such as provenance, i.e. the original source
where the data came from and how it was generated [13][14]. There are four main
Semantic Web standards for knowledge representation: Resource Description Frame-
w o r k( R D F ) ,R D FS c h e m a( R D F S ) ,W e bO n t o l o g yL a n g u a g e( O W L ) ,a n dS P A R Q L
query language.
Ontologies, which formalize the meaning of terms used in discourse, are expected to
play a major role in the automated integration of patient data with relevant informa-
tion to support basic discovery and clinical research, drug formulation, and drug eva-
luation through clinical trials. Already, OWL ontologies have been developed to
support drug, pharmacogenomics and clinical trials [15][16][17], provide a mechanism
for the integration and exchange of biological pathways [18,19], and are increasingly
being used in health care and life sciences applications [20]. Another W3C standard,
Gleaning Resource Descriptions from Dialects of Languages (GRDDL) enables users to
obtain RDF triples out of XML documents. Collectively, these next generation Seman-
tic Web technologies provide the resources required to systematically re-engineer both
EHR and research data warehouse systems. This will make it easier and more practical
to integrate, query, and analyze the full spectrum of relevant laboratory and clinical
research data, as well as EHRs, in supporting the development of cost effective and
outcome-oriented systems.
In this paper, participants in the Translational Medicine task force of the World
Wide Web Consortium’s Health Care and Life Sciences Interest Group (W3C
HCLSIG) present the Translational Medicine Ontology (TMO) and the Translational
Medicine Knowledge Base (TMKB). The TMKB consists of the TMO, mappings to
other terminologies and ontologies, and data in RDF format spanning discovery
research and drug development, which are of therapeutic relevance to clinical research
and clinical practice. The TMO provides a foundation for types declared in Linking
Open Drug Data (LODD) [21] and EHRs. The TMO captures core, high-level termi-
nology to bridge existing open domain ontologies and provides a framework to relate
and integrate patient-centric data across the knowledge gap from bench to bedside.
With the TMO and TMKB, we demonstrate how to bridge the gap and how to
develop valuable translational knowledge pertinent to clinical research, and therefore
to clinical practice.
The remainder of the paper is structured as follows: we describe the use case for the
TMKB, which centers around Alzheimer’s Disease (AD), then describe the methods
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then explore pertinent questions that the TMKB can answer in the results, discuss our
findings, and conclude with a listing of unsolved problems and possible future direc-
tions for this work.
Use case
Alzheimer’s Disease (AD) is an incurable, degenerative, and terminal disease with few
therapeutic options [22][23]. It is a complex disease influenced by a range of genetic,
environmental, and other factors [23]. Recently, Jack et al.[24] demonstrated the value
of shared data in AD biomarker research. A New York Times article on the role of
data sharing, in the advancement of AD research, quotes John Trojanowski at the Uni-
versity of Pennsylvania Medical School: “It’s not science the way most of us have prac-
ticed it in our careers. But we all realized that we would never get biomarkers unless
all of us parked our egos and intellectual-property noses outside the door and agreed
that all of our data would be public immediately.” [25] Efficient aggregation of relevant
information improves our understanding of disease and significantly benefits research-
ers, clinicians, patients and pharmaceutical companies.
We demonstrate the usefulness of TMO and TMKB in a use case that follows a
patient and physician from a first report of symptoms, to diagnosis of AD, selection of
an optimal treatment regimen, consideration of alternative treatments following the
report of side effects caused by the initial treatment, and finally to the selection of pos-
sible appropriate clinical trials for the patient.
The Alzheimer’s Disease patient use case can be summarized in the following way:
1. A patient and family members report symptoms to a physician/clinician. The phy-
sician/clinician enters the reported symptoms into an EHR. All concepts are mapped to
URIs with the help of TMO.
2. The physician makes a list of differential diagnoses, with a working diagnosis of
AD.
3. The physician arranges for the patient to have a basic biochemical, haematological,
and SNP profile undertaken. Biochemistry, haematology, and SNP requests are input
directly by the various respective departments into the patient’s EHR. Preliminary SNP
and genetic data will be submitted directly to the NIH Pharmacogenetics Research Net-
work (PGRN).
4. A follow-up meeting is scheduled to perform a set of diagnostic tests outlined by
what the clinician feels initially are most appropriate for disease presentation.
5. The physician continues to add investigations/lab results to the patient’sE H Ra n d
these are combined with the patient’s medical history information. A disease is chosen
as the most likely of the listed differential diagnoses based on all of the information
provided.
6. The physician confirms and now has a refined and widely acceptable diagnosis of
AD with behavioral assessments, cognitive tests, and appropriate brain scan if indicated
and enters the diagnosis data into the patient’s EHR.
7. The physician selects the most appropriate AD drug and clinical protocol from the
patient’s medical record based on the severity of the disease, the patient’s SNP profile
(ADME, efficacy/safety based on presence or absence of receptors), patient’sB M I ,a n d
concurrent medication, and drug availability on Medicare D. Fundamental questions
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neously or in a specific order:
￿ What are the clinically recommended agents?
￿ What products are available for prescription, and which are legally indicated for
AD disease?
￿ What is the SNP verdict? These agents are sourced with a pharmacogenomics data-
base to determine
– Will they be efficacious? Is the disease receptor positive?
– Will they be harmful? Are there toxic metabolites? Is CYP 450 or acetylator status
available?
￿ Are the preceding predictive genetic SNP tests covered by the patient’si n s u r a n c e
company? Are the resulting pharmaceutical agents covered by the patient’ss p e c i f i c
insurance?
8. The physician checks with the pharmacist, or consults drug information literature
to avoid potential drug interactions.
9. The physician now prescribes Aricept (Donepezil) as it satisfies criteria listed above.
It is indicated, safe, effective, available, there are no drug interactions issues with drug
delivery, and it is covered by the insurance.
10. In a follow-up visit the patient later reports nausea from Donepezil. The physician
is aware of this common side effect (other side effects reported include bradycardia,
diarrhea, anorexia, abdominal pain, and vivid dreams etc...), and re-consults the litera-
ture to ensure this is acceptable and agreeable with patient. The physician documents
the side effect for post-marketing adverse event pick-up and future study. He changes
medication if necessary or adds another medication to alleviate side effects.
11. The physician considers moving the patient to a trial. The physician obtains infor-
mation on all (local, national, and international trials) for AD. Trials might be listed
in data sources from the FDA, WHO, ClinicalTrials.gov, Citeline TrialTrove, etc.; aca-
demia or pharma may also solicit patients, or the physician may point the patient to
investigators undertaking a trial.
￿ The physician decides whether
– to enroll the patient in a clinical trial as one of the agents looks very suitable and
may benefit patient, or because the patient is interested in participating in the trial;
– not to enroll the patient because the trial is unsuitable or the patient declines to
participate in the trial;
– to obtain information for the patient on a trial appropriate for the patient with
potential of future enrollment.
12. The physician checks if the patient meets trial inclusion/exclusion criteria by
querying the EHR.
13. The patient has a thorough medical assessment (lifestyle, medical history, geno-
mics, proteomics, metabolomics, images, cognition) to supplement and update existing
data.
14. The results of the medical exam influence the arm of the trial in which the
patient participates. The patient status is updated.
Questions relevant for this use case scenario are listed in Table 1. Such questions
can be formulated in SPARQL queries (see section SPARQL queries, and additional
file 1) and answered using TMKB.
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Please refer to the public wiki page for specific URLs of resources described herein
[26]. As part of its requirements analysis, the HCLSIG Translational Medicine task
force identified seven use cases against which its activities would be measured. These
include scenarios involving chemogenomics, animal models, pharmacogenomics, thera-
peutic development, patient care, and integrative informatics (see wiki for full details
of each use case). The work presented here follows questions asked in the patient care
scenario that are related to the user roles and interests summarized in Table 2.
Table 1 Questions and answers using TMO-integrated data sources
Question Answer
Clinic
What are the diagnostic criteria for AD? There are 12 diagnostic inclusion criteria and 9
exclusion criteria.
Does Medicare D cover Donepezil? Medicare D covers 2 brand name formulations of
Donepezil: Aricept and Aricept ODT.
Have any AD patients been treated for other
neurological conditions?
Patient 2 was found to suffer from AD and depression.
Clinical Trial
Since my patient is suffering from drug-induced side
effects for AD treatment, can an AD clinical trial with
a different mechanism of action (MOA) be identified?
Of the 438 drugs linked to AD trials, only 58 are in
active trials and only 2 (Doxorubicin and IL-2) have a
documented MOA. 78 AD-associated drugs have an
established MOA.
Find AD patients without the APOE4 allele as these
would be good candidates for the clinical trial
involving Bapineuzumab?
Of the four patients with AD, only one does not carry
the APOE4 allele, and may be a good candidate for
the clinical trial.
What active trials are ongoing that would be a good
fit for Patient 2?
58 Alzheimer trials: 2 mild cognitive impairment, 1
hypercholesterolaemia, 66 my-ocardial infarction, 46
anxiety, and 126 depression.
Research
What genes are associated with or implicated in AD? Diseasome and PharmGKB indicate at least 97 genes
have some association with AD.
Which SNPs may be potential AD biomark-ers? PharmGKB reveals 63 SNPs
Which market drugs might potentially be re-purposed
for AD because they modulate AD implicated genes?
57 compounds or classes of compounds that are used
to treat 45 diseases, including AD, hyper/hypotension,
diabetes and obesity.
Table 2 Users and their interests in translational medicine
Category User Interest
Research Biologist (in vivo, in vitro, cellular &
molecular)
Target identification, assay development, target
validation
Bioinformatician Biological knowledge management, cellular modeling
Immunologist Natural defense mechanisms
Cheminformatician Predictive chemistry
Medicinal chemist Drug efficacy
Systems physiologist Tolerance, adverse events
Clinic Clinical trial specialist Trial formulation, recruitment
Clinical decision support Data analysis, trend finding
Primary care physician General, conventional care
Specialty medical provider Specialized treatments
Business Sales & marketing Revenue generation
Strategic/portfolio manager Assessing market opportunities
Project manager Prioritizing resources & activities
Health plan provider Insurance coverage
Luciano et al. Journal of Biomedical Semantics 2011, 2(Suppl 2):S1
http://www.jbiomedsem.com/content/2/S2/S1
Page 7 of 21We present the major components of the TMKB, namely the ontology used as a fra-
mework for data integration and the various datasets integrated in our knowledge base.
We also outline the processes that we developed for ensuring the consistency of the
knowledge base and the ontology.
Ontology design
The scope of the Translational Medicine Ontology (TMO) is defined by the use case
terminology and respective data sources. Each term and corresponding data source
was analyzed for its conceptual, representational and reasoning capability as required
by the use case requirements. TMO terms were obtained from a lexical analysis of
sample research questions from 14 types of users, all of whom were involved in aspects
of research, clinical care and or business (Table 2). Terms were formalized as referring
to classes, relations or individuals in the OWL ontology. Terms that appear in state-
ments that hold in general (e.g. “patients participate in consultations” and “active
ingredient is a role played by a molecular entity”) form key background knowledge,
refer to instantiable types and are represented as classes in the ontology. Eighty classes
were created to represent material (e.g. molecule, protein, cell lines, pharmaceutical
preparations), processual (e.g. diagnosis, study, intervention), qualitative, role (e.g. sub-
ject, target, active ingredient) and informational entities (e.g. dosage, mechanism of
action, sign/symptom [27], family history) of relevance to our study. By contrast, parti-
culars (e.g. “ap a t i e n tw i t hag i v e nn a m e ” and “a blister package of a pharmaceutical
product with a particular identifying code on it”) refer to individuals and are repre-
sented as instances of classes in the ontology. Consequently, a particular consultation
at a given time and day, the particular patient role in that consultation, and the physi-
cian role in that consultation can be represented as instances of classes in the
ontology.
Figure 1 shows a portion of the TMO and illustrates selected types, subtypes, and
existential restrictions that hold between types. For instance, chemical substances are
chemical entities that are composed of molecular entities. A key part of designing
the ontology involved disambiguating polysemous terms e.g. “drug.” A drug can refer
to the whole pharmaceutical product or to the active ingredient. The TMO
Figure 1 TMO overview. Overview of selected types, subtypes (overlap) and existential restrictions
(arrows) in the Translational Medicine Ontology.
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molecules, “active ingredient” (TMO _0000) for biologically active chemicals in for-
mulated pharmaceuticals, “formulated pharmaceutical” (TMO _0001) for a substance
that may or may not have been approved by a regulatory authority, and “pharmaceu-
tical product” (TMO _0002) for a drug approved by a regulatory authority. The
TMO extends the basic types defined in the Basic Formal Ontology and uses rela-
tions from the Relation Ontology [28]. Given the prevalence of the terms defined in
t h eo n t o l o g ya n dt h ed e s i r et oe s t a b l i s hthe TMO as a global ontology, we also cre-
ated 223 class equivalence mappings (using owl:equivalentClass)f r o m6 0T M O
classes to 201 target classes from 40 ontologies (see Table 3; Figures 2 and 3). These
mappings were manually identified and verified using the NCBO BioPortal [29] and
UMLS [30]. Finally, in order to create a stable, consistent ontology, we import one
document (TMO-external.owl) as the aggregation of all externally dependent ontolo-
gies, including: Basic Formal Ontology (BFO), Relation Ontology (RO), and Informa-
tion Artifact Ontology (IAO).
The TMO was built using Protégé 4.0.2 and is represented as an OWL2 compliant
ontology. TMO Terms are defined in the http://www.w3.org/2001/sw/hcls/ns/
transmed/ namespace. See public wiki to obtain the ontology.
Data sources
The data sources used in this study include formulary lists, pharmacogenomics infor-
mation, clinical trial lists, and scientific data about marketed drugs (Table 4). Clinical-
Trials.gov is a registry of clinical trials, AD diagnostic refers to a formalized version of
the diagnostic criteria for Alzheimer’s Disease described in Dubois et al. [31] , Dai-
lyMed contains marketed and FDA approved drugs, Diseasome contains information
about gene-disease associations, DrugBank [32] contains detailed drug and drug target
data, Medicare contains Medicare Part D approved drugs, Patient contains the syn-
thetic patient data created for use in this study, PharmGKB [33] contains data about
drug response associated with genetic variation and SIDER identifies side effects asso-
ciated with marketed drugs.
All datasets, except for PharmGKB, diagnostic criteria, and patient records, are avail-
able through the LODD project [21]. PharmGKB is made available as part of the
Table 3 Representative mappings between TMO and target terms
Label TMO Target
Protein 0035 ACGT:Protein, BIRNLex:23, CHEBI:36O8O, FMA:Protein, GO:OOO3675, GRO:Protein, Galen:
Protein, NCIt:Protein, PRO:00000000l, SNOMEDCT:88878007, SO:0000358, UMLS:C0033684
Gene 0037 FMA:Structural gene, GRO:Gene, Galen:Gene, LNC:LP32747-5, MSH:D005796, NCIt:Gene, NCIt:
Gene_ Object, NDFRT:C242394, PRO:Gene, SNOMEDCT:6727l00l, SO:0000704, UMLS:C00I7337
Diagnosis 0031 ACGT:Diagnosis, FHHO:Diagnosis, Galen:Diagnosis, LNC:LP72437-4, MSH:D003933, NCIt:
Diagnosis, OBI:0000075, OCRe_clinical:Diagnosis, SNOMEDCT:439401001, UMLS:C0011900
Disease 0047 ACGT:Disease, BIRNLex:ll0l3, DOID:4, GRO:Disease, LNC:LP21006-9, MSH:D004194, NCIt:Disease_
or_ Disorder, NDFRT:C2140, OBI:0000155, UMLS:C0012634
Abbreviations: ACGT- ACGT Master Ontology, NIFSTD – Neuroscience Information Framework Standardized ontology,
CHEBI – Chemical Entities of Biological Interest, CTO – Clinical Trial Ontology, DOID – Human Disease Ontology, FMA –
Foundation Model of Anatomy, FHHO – Family Health History Ontology, Galen – Galen Ontology, GO – Gene Ontology,
GRO – Gene Regulation Ontology, LNC – Logical Observation Identifier Names and Codes, MSH- Medical Subject
Headings, NCIt – NCI theraurus, NDFRT – National Drug File, OBI – Ontology for Biomedical Investigation, OCRe -
Ontology for Clinical Research, PATO – Phenotypic Quality Ontology, PRO – Protein Ontology, SNOMED CT, SNOMED
clinical terms, SO – Sequence Ontology, UMLS – Unified Modeling Language System.
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Medicine wiki. [26] Seven synthetic patient records were manually created to capture
typical medical record data: demographic information, contact information, family his-
tory, life style data, allergies, immunizations, information on conditions, procedures,
prescriptions, and visits to health care providers. These records are by no means com-
plete, or unabridged. In practice, clinicians often base care on similar records when
treating patients. Patients typically seen by care providers in one health care network,
using one EHR system, may visit another hospital outside their network that uses a
completely different EHR system. This results in an unfortunate, but common real-
world scenario that forces the creation of a duplicate EHR, often simplistic and based
largely on the data contained in the previous system. In many instances, crucial infor-
mation is transferred via telephone to the new provider because alternative means are
often not yet in place to enable electronic transfer or interoperability in a timely fash-
ion. In this way, the patients created for the TMO reflect the type of health record one
could expect to see in clinical practice. They are basic, yet contain enough data to
demonstrate a foundation for more complex query as standardized systems become
more prevalent.
The United States Department of Veterans Affairs currently maintains one of the
most comprehensive EHR repositories, the Computerized Patient Record System
(CPRS), which is managed with the related clinical VistA software. A patient’sm e d i -
cal record within this system will likely contain far more detail than the simulated
patients we have created for TMO. If a patient visits any facility within the Veteran’s
N e t w o r k ,ac o m p l e t eu n a b r i d g e dm e d i c a lr e c o r di sf u l l ya c c e s s i b l ea n dm a yb e
updated by all who access this record. Often times, patients never leave this network
Figure 2 Query #1: Side effects. The data elements involved in query #1. The query can be formulated
as “How many patients experienced side effects while taking Donepezil?”
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a hospital outside this network, as described above, only relevant details pertaining
to their care are transferred. A new, abridged EHR is then re-created at each new
institution, in much less detail, and is largely similar to the simulated patients
designed for TMO.
Our records were, to a large extent, built upon the XML-based Indivo specification
for personally-controlled health care records. The Indivo initiative [35] offers simple
user interfaces to store records and to grant others controlled access to them. Archiv-
ing systems like i2b2’s database records and Indivo’s XML records can generically
record data, such as test results, in tuples that include a coding system, a code, a tested
Table 4 Data sources used in this study
LODD Prefix Dataset Description
x linkedct Clinicaltrials.gov Registry of clinical trials
dubois AD diagnostic AD diagnostic criteria
x dailymed DailyMed Marketed & FDA approved drugs
x diseasome Diseasome The genetic basis of disease
x drugbank DrugBank Detailed drug data & drug target
x medicare Medicare Medicare D approved drugs
pchr Patient synthetic patient data
pharmgkb PharmGKB Drug response to genetic variation
x sider SIDER Side effects of marketed drugs
LODD –‘ x’ indicates a Linking Open Drug Data dataset
Figure 3 TKMB overview. Overview of the contents of the Translational Medicine Knowledge Base
(TMKB). TMKB is composed of the Translational Medicine Ontology with mappings to ontologies and
terminologies listed in the NCBO BioPortal. The TMO provides a global schema for Indivo-based electronic
health records (EHRs) and can be used with formalized criteria for Alzheimer’s Disease. The TMO maps
types from Linking Open Data sources.
Luciano et al. Journal of Biomedical Semantics 2011, 2(Suppl 2):S1
http://www.jbiomedsem.com/content/2/S2/S1
Page 11 of 21value, and the units of the value. For example, a systolic blood pressure measurement
might be listed using a SNOMED CT code and mmHg units as in the example below:
_:X a  :VitalSign ;
              \ :dateMeasured 2010-11-12T18 8:03Z"^^xsd:dateTime ;
            :type <http://...umls-sn nomed#_BPsys> ;
            : \ "^^   value http codesin 130 < :// . d divoorg units mmHg ./ / . # >
We used GRDDL/XSLT to define an RDF representation for Indivo patient records.
A straightforward RDF representation of the above XML is:
_:X a  :VitalSign ;
              \ :dateMeasured 2010-11-12T18 8:03Z"^^xsd:dateTime ;
            :type <http://...umls-sn nomed#_BPsys> ;
            :  \ "^^ value 130 <http://codes.ind divo.org/units/ mmHg>. #
Where possible, this representation instantiates types in the TMO ontology. How-
ever, this representation leaves the consumer having to normalize (e.g. MPa to mmHg)
before comparing or reporting values of potentially different units. Representing fre-
quently needed and commonly used vital signs in a normalized form simplifies the
effort needed to reuse these data:
_:X :systolicBPpascals 173322 <http://... Pascals>.  \" ^ ^ #
Including the generic and the “standardized” forms allows us to meet a wide range of use
cases and the tension between flexibility and predictability is the crux of the art of standards.
Given that an XSLT stylesheet converts the XML-based Indivo data to instances of
TMO classes, the mapping process should also perform this normalization. Currently,
w en o r m a l i z eo n l yas m a l ls e to fv i t a l sa sap r o o fo fc o n c e p t ,b u tt h i si se x p e c t e dt o
expand as we draw on more diverse data.
Incremental-test-driven development
In order to keep our queries synchronized with the data model, we developed a simple
test mechanism based on a practice of incremental development and testing. When
changes are made to the data, incremental testing provides an efficient way to test all
the known queries that area impacted by the changes. Practically, this means critiquing
the accuracy of the RDF representation, deciding whether it should be modeled differ-
ently, making changes (in our case, to the XSLTs which generate the RDF), and finally
invoking the unit testing system to determine whether queries can still be answered.
The advantages of this workflow are increased accountability, increased agility/confi-
dence, and error messages tied to recent edits. Our testing strategy could be described
as “Extreme Ontology Development” akin to a programming methodology called
“Extreme Programming” which incorporates regular and automated testing of essential
application features into the development cycle and increases vigilance to the inadver-
tent errors that are typically introduced during development.
Data mapping
The user roles and interests listed in Table 2 are related to the patient scenario use
case described in 14 steps above and in greater detail on the public wiki. The first step
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terms and a standard ontology that contains that term. In the absence of identical
matches on the labels, the Linkage Query Writer (LinQuer) tool was used to create
mappings between LODD datasets [36], along with Silk [37], which employs similarity
metrics including string, numeric, data, URI, and set comparison methods. Entity iden-
tity was asserted using owl:sameAs. The mappings were augmented by those provided
for PharmGKB via Bio2RDF [34]. Mappings between LODD dataset types and the
TMO types were established using owl:equivalentClass.
TMKB
The TMKB is an RDFS-reasoning-capable Semantic Web knowledge base composed of
the TMO, RDFized datasets, and equivalence mappings (Figure 3). The TMO, dataset,
and mapping files were loaded into OpenLink Virtuoso 6 open source community edi-
tion, and is made available as a SPARQL endpoint and a faceted text search interface.
The consistency of the knowledge base was checked with using the OWL2 RL reason-
ing capabilities of BigOWLIM.
Results and discussion
Translational medicine requires the full extent of patient data to be accessible so
that questions spanning multiple data sources, such as those discussed above, can be
asked and answered. For example, a physician in clinical practice would like to easily
ask for the criteria for the diagnosis of a disease and the recommendations for perso-
nalized medicines. However, TMKB has the potential to be equally relevant to scien-
tists developing new pharmaceutical products. While simple questions may be
answered by queries on a single data set, other scientific questions may be addressed
only when diverse data sets are fully integrated [38]. Importantly, answering more
sophisticated questions may require inference i) over the subclass hierarchy of TMO
types or ii) through equivalence mappings. Examples of queries that can now be exe-
cuted with SPARQL are listed in Table 1, with the full list available on the public
wiki.
One ongoing issue in translational informatics is patient privacy and the security of
data. An approach that has been pursued using semantic technologies is to encode
data access rules and then check all data accesses against these policies [39]. For exam-
p l e ,ap o l i c yc a ng i v eah o s p i t a lb i l l i n gs p e c i alist access to data about procedures per-
formed at the hospital for the purpose of insurance billing. Then, when procedure data
is requested, the requester would need to show that they were a billing specialist and
provide the purpose for which they want to access the data. Semantic technologies can
be and have been used to encode the policies, recognize compliance (or non-compli-
ance), and explain results.
SPARQL queries
To demonstrate the utility of the TMO and TMKB, we created fourteen questions to
represent the intent of the use case. The questions have been included in this section
of the document and are available on the public wiki. The wiki also contains the
SPARQL source code and a clickable link that runs the query against the TMKB and
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responding SPARQL source code and a hyperlink to the results of the first ten. The
fourteen queries are reproduced below. The SPARQL source code and results are pre-
sented for two selected queries. These queries use the synthetic patient data. To run
the queries, click on the link (where provided) or copy the text of the SPARQL query,
paste it into the query text box at http://tm.semanticscience.org/sparql and click on
“Run Query” button.
The significance of the SPARQL queries we present is to demonstrate that several
different types of investigation, spanning information from different disciplines, can be
carried out from the same query interface. In the hospital or clinic, the often fragmen-
ted information systems do not interoperate, requiring analogous investigations to
coordinate between different specialists with access to different types of information.
The combination of disparate types of information sources such as EHRs with clinical
trial information, information about drugs and adverse reactions, as well as information
about genetic variants, is crucial to reaching the goals of personalized medicine. It is
precisely this type of information integration that is enabled by linked data approaches
such as the one described here.
1. How many patients experienced side effects while taking Donepezil?
2. What are the diagnostic criteria for Alzheimer’s Disease (AD)?
3. Is Donepezil covered by Medicare Part D?
4. Have any of my AD patients been treated for other neurological conditions as this
might impact their diagnosis?
5. Are there other clinical trials that my patient may participate in for AD which
have a different mechanism of action than the patient’s current drug because it caused
side effects?
6. Are there any AD patients without the APOE4 allele as these would be good candi-
dates for the clinical trial involving Bapineuzumab?
7. What active trials are ongoing that would be a good fit for Patient 2?
8. Do I have suitable patients for an AD trial where they are looking for females who
are aged over 55 years, have the APOE variant, and low ADAS COG scores?
9. What genes are associated with or implicated in AD?
10. What biomarkers are associated with or implicated in AD?
11. An APOE variant is strongly correlated with AD predisposition. Are there drug
classes and drugs that target APOE?
12. Which existing marketed drugs might potentially be re-purposed for AD because
they are known to modulate genes that are implicated in the disease?
13. What are the results of patient Georg Steffen Möller’s lipid panel?
14. What is patient Monica Mary Mall’s platelet count over time?
F i n d i n ge l i g i b l ep a t i e n t sc a nb eac o s t l ye n d eavor for clinical trials so systems that
facilitate this activity can save significant costs, as well as increase the effectiveness of
treatment. The following query demonstrates the ability to perform patient eligibility
studies when the appropriate information is accessible. The use case involves identify-
ing patients without the APOE4 genetic allele for a particular clinical trial. APOE4 is
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copies of the ApoE4 variant exhibit an increased risk of developing late onset (type 2)
Alzheimer’s Disease.
Query #6: Are there any AD patients without the APOE4 allele as these would be
good candidates for the clinical trial involving Bapineuzumab?
The corresponding SPARQL query is:
PREFIX trans: <tag:eric@w3.org:2009/tmo/translator#>
PREFIX   foaf: <http://xmlns.com/foaf/0.1/>
SELECT DISTINCT ?name ? ?patient
WHERE {
   ?patient
        trans:hasCondition [
                trans:diagnosedWith trans:alzheimers_disease
          ] ;
        foaf:name ?name .
   OPTIONAL {
       ?enc counter trans:test [
            a ?testname ;
            t trans:result ?result
        ] .
       ?result
            t trans:feature trans:variant_APOE4 ;
            trans:prese ent true .
   }
   FILTER ( !bound(?result) ) .
}
The results to this query are listed in table 5.
This next query presents an example of discovering novel uses for existing mar-
keted drugs. We understand this to be of interest to the pharmaceutical industry
because of the huge savings in time and money for development and clinical trials.
The benefits also translate to physicians and patients because medicines may be
available sooner to help manage medical conditions. This query takes advantage of
the information in PharmGKB, in which the relations between genes, drugs, and dis-
eases are tracked.
Qquery #12: Which existing marketed drugs might potentially be candidates for AD
because they are known to modulate genes that are implicated in the disease?
Table 5 Query results for query #6
name patient
Benny Smith http://tag:ericw3.org:2009/pchr/3#me
Georg Steffen Möller http://tag:ericw3.org:2009/pchr/5#me
AD patients in TMKB without the APOE4 allele as these would be good candidates for the clinical trial involving
Bapineuzumab.
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PREFIX pharmgkb: <http://bio2rdf.org/pharmgkb:>
SELECT DISTI INCT ?drug_name ?disease2_name
WHERE {
   GRAPH <pharmgkb> { {
                   ?association rdf:type pharmgkb:DrugGen neVariantInteraction .
                   ?association phar rmgkb:description ?description .
                   ?associ iation pharmgkb:disease
                      <http://bio2r rdf.org/pharmgkb:1aa122e7b0687fa04b895ee82d6b6476> .
                     ?association pharmgkb:variant ?variant .
                     ?association pharmgkb:gene ?gene .
                     ?gene dc:identifier ?gene_name .
                     ?a2 a pharmgkb:Association .
                   ?a2 p pharmgkb:gene ?gene .
                   ?a2 pharmgkb:disea ase ?d2 .
                   ?d2 rdfs:label ?disease2_name   .
                   ?a2 pharmgkb:drug ?drug .
                     ?drug rdfs:label ?drug_name .
    }
}
ORDER BY ASC(?d drug_name) ASC(?disease2_name)
The first 25 results to this query are listed in table 6.
Related work
Translational medicine, the integration of the research pipeline from bench to bedside
and back, has been a high priority for national biomedical research programs around
the world. NIH’s Clinical and Translational Science Awards (CTSAs), set forth by Zer-
houni [40], provide leadership in translational research and have been fruitful in pro-
ducing semantic translational informatics projects [41]. In Europe, Kamel et al.[42]
introduced the Innovative Medicine Initiative (IMI), a joint undertaking between the
European Union and the pharmaceutical industry association, European Federation of
Pharmaceutical Industries and Associations (EFPIA). Translational informatics has long
been a use case for biomedical semantics. Earlier work by the HCLSIG showed the
potential of Semantic Web technologies for translational research [43]. Use cases such
as those described in Kashyap et al.[44] are being addressed through a number of pro-
jects, such as the BRIDG model, a joint project between the Clinical Data Interchange
Standards Consortium (CDISC), the HL7 Regulated Clinical Research Information
Management Technical Committee (RCRIM TC), the National Cancer Institute (NCI),
and the US Food and Drug Administration (FDA). The goal is to produce a shared
view of the dynamic and static semantics for protocol-driven research. [45] Other
efforts have included development of large-scale terminologies, such as the NCI The-
saurus [46] and the Systematized NOmenclature of MEDicine Clinical Terms
(SNOMED CT) [47]. The Informatics for Integrating Biology and the Bedside (i2b2)
[48] project has developed a platform to integrate data from diverse sources, including
free text and structured databases.
Luciano et al. Journal of Biomedical Semantics 2011, 2(Suppl 2):S1
http://www.jbiomedsem.com/content/2/S2/S1
Page 16 of 21Conclusions
The Translational Medicine Ontology supports translational medicine by providing a
model that facilitates interoperability of data from bench to bedside. Our Alzheimer’sD i s -
ease focused use case demonstrates the use of the Translational Medicine Knowledge Base
in translational research in the context of a well known disease. The TMKB has also been
shown as a good candidate for providing more personalized information for patient treat-
ment. While the medical history of our sample patients is not extensive, it reflects the rea-
lity of incomplete medical records in practice today within many institutions. Consistency
and completeness of Electronic Health Records will be increasingly important in collabora-
tions between researchers and physicians. More effective integration of data, as we have
demonstrated here through the use of applied ontological methods, should enable data
mining in a clinical setting to identify superior efficacy of certain drugs over others in speci-
fic sections of the population. “Patterns” detected in large data repositories can only be
accurately detected if the form and consistency of data is assured. “Noisy” or contaminated
data can generate false patterns or generate sufficient noise that true patterns are unde-
tected. A clinician should be able to efficiently obtain a list of safe, effective, evidence-based
therapies for administration to a specific patient while considering what payers can afford.
Since our work specifically focused on integrating existing datasets using a common
vocabulary, we inevitably acquired terms that are either difficult to define within the
Table 6 The first 25 query results for query #12
drug name disease2 _name
(s)-rolipram Schizophrenia
(s)-rolipram Autistic Disorder
(s)-rolipram Bipolar Disorder
(s)-rolipram Depression
ACE INHIBITORS, PLAIN Angioneurotic Edema
ACE INHIBITORS, PLAIN Hypertension
ACE INHIBITORS, PLAIN Hypertrophy, Left Ventricular
ACE INHIBITORS, PLAIN Coronary Disease
ACE INHIBITORS, PLAIN Alzheimer Disease
ACE INHIBITORS, PLAIN nondiabetic proteinuric nephropathy
ACE INHIBITORS, PLAIN Alcoholism
ACE INHIBITORS, PLAIN Abnormalities
ACE INHIBITORS, PLAIN Fetal Death
ACE INHIBITORS, PLAIN Cardiovascular Abnormalities
ACE INHIBITORS, PLAIN Cardiovascular Diseases
ACE INHIBITORS, PLAIN Cough
ACE INHIBITORS, PLAIN Heart Failure
ACE INHIBITORS, PLAIN Kidney Diseases
ANGIOTENSIN II ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS Cardiovascular Diseases
ANGIOTENSIN II ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS Hypertension
ANTIPSYCHOTICS Schizophrenia
BETA BLOCKING AGENTS Abnormalities
BETA BLOCKING AGENTS Fetal Death
BETA BLOCKING AGENTS Cardiovascular Abnormalities
atenolol glomerulosclerosis
... ...
A selection of existing marketed drugs in TMKB that might potentially be candidates for AD because they are known to
modulate genes that are implicated in the disease.
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example, the term “side effect” is particularly challenging because side effects in them-
selves are so varied in their classifications. For example, nightmares are considered
processes, but tender gums are dispositions that are realized in processes (sensation of
pain in gums when palpated). While the TMO has “adverse drug event” (TMO 0043),
it will take time and effort to correctly assign the full set of side effects listed in SIDER.
In addition to the significant health related need for a uniform ontology, in the US,
there are now approximately 55 Clinical and Translational Science Centers with
approximately 5 more centers to be funded. Each center provides a robust informatics
core supporting the entire spectrum of translational science activity. At present,
approximately half of the funded centers and some additional 20 research and com-
mercial biomedical research groups around the world use Harvard Medical School’s
i2b2 platform. The i2b2 system provides a tremendous opportunity to test TMO’s
impact in a broad collection of translational medicine programs and projects. We
intend to incorporate the current release of TMO into the i2b2 platform and design a
set of pilot projects using TMO to accelerate the research and clinical efforts.
Future work will focus on entities related to drug discovery and drug development in
order to increase its utility for the pharmaceutical industry. We aim to incorporate
pathway references [49] to support a greater number of pharmaceutical industry use
cases. A broader goal is to enable interoperability with large scale e-Science work [50]
[51]. In order to do this, the underlying representation needs to be expanded to
include provenance. Encodings could be done in a provenance interlingua such as the
Proof Markup Language [52] or the Open Provenance Model [53]. Sahoo has proposed
a method for recording provenance information directly in RDF [54]. Many interdisci-
plinary e-Science efforts find that they need to provide services to access information,
such as the sources relied on to generate a conclusion, the transformations applied to
the data, or assumptions embodied in the data. Further, we hope to support deeper
semantic scientific knowledge integration [55]. We also hope to engage in the evalua-
tion of data to identify potential inconsistencies and readiness for use. We have utilized
logical consistency checking, such as the services available by state of the art OWL rea-
soners, but we may expand to either utilize or build evaluation services that may, for
example, check instance data for possible problems, such as those encountered at the
border between open and close-world reasoning [56]. Given the project’sr e l i a n c eo n
equivalence links, we may explore using other types of equivalence or similarity rela-
tionships, such as those in [57], [58].
Another key goal is the development of a role-based user interface that would encou-
rage vendors of EHRs to use ontologies, such as the TMO, and ontology-enhanced ser-
vices not only to guide question answering ,b u ta l s ot oi m p r o v er e p r e s e n t a t i o na n d
integration of data [59]. The TMKB is intended to provide a first step towards normal-
izing the sharing and integration of research and clinical artifacts. We wish to enable
scientists to capitalize on the benefits derived from open data, communities of practice,
and Semantic Web technology for reasoning across vast amounts of health care and
life science data. The TMO can also be used to power a set of ontology-enhanced ser-
vices, such as ontology-enhanced search, provenance, and verification services, thus
helping to improve accuracy, trust, and accountability of scientific information. And
lastly, we would like to support emerging semantic publishing, referencing, and
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those ontologies.
Additional material
Additional file 1: Supplement 01 (v03) to “The Translational Medicine Ontology and Knowledge Base:
Driving personalized medicine by bridging the gap between bench and bedside” A supplemental
document containing the TMKB SPARQL queries and results created for this manuscript.
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